Sprint Bioscience

Name: Sprint Bioscience
Address: Hälsovägen 7, Huddinge, 14152, SE
Telephone: +4684114455

Hem
Sverige
Huddinge
Sprint Bioscience

Sprint Bioscience is a complete pharmaceutical company focused on developing new innovative drugs to

Sprint Bioscience is an agile and innovative company that develops pharmaceuticals in the areas of cancer. Since our inception in 2009 we have built a body of solid expertise and achieved a world leading position, thanks to our dedicated and skilled employees and our effective methodology. OUR BUSINESS CONCEPT

Our strategy is to work with a broad portfolio of projects which we quickly develop in

the preclinical stage, until we have identified a drug candidate that is ready for clinical trials. We enter into commercial partnerships with pharmaceutical companies at an early phase. Our partner then drives the project forward through the clinical phases and onto the market. We occupy modern laboratories at Novum in Huddinge with access to all the equipment required to pursue advanced drug development.

28/05/2026

Tune in to hear Sprint Bioscience featured on the Market Makers podcast🎙️CEO Johan Emilsson joins for an interview.

Market Makers is one of Sweden’s largest finance podcasts, focusing on investments in growth and technology stocks. Since its launch in 2017, the podcast has accumulated over 4 million listens and built a loyal audience. New episodes are released every Thursday, featuring stock cases, market insights, and analysis across sectors.

In the latest episode, Johan talks about what we do at Sprint Bioscience and, most importantly, how we do it, while also answering questions about our business and strategy.

📻 Listen to the episode here (available in Swedish): https://shows.acast.com/marketmakers/episodes/434-kina-och-norgerisken

25/05/2026

Now available: watch the recordings from Global Forum 2026, including Sprint Bioscience CEO Johan Emilsson presenting the company:
🎥 https://biostock.se/2026/05/sprint-bioscience-global-forum-2026/
The event gathered a strong international audience of investors, BD&L representatives, and industry experts. Through several engaging and insightful panel discussions, key topics such as global market expansion, strategic partnerships, and access to international capital were explored.

A big thank you to the organizers BioStock - Connecting Innovation & Capital for a well-executed and rewarding event.

Foto by: Johan Bävman

15/05/2026

Sprint Bioscience’s interim report for the first quarter was published this Wednesday.
Johan Emilsson, CEO of Sprint Bioscience, says: “The first quarter of 2026 has been intense and highly productive. We have taken several important steps forward in our programs, broadened the medical and commercial value of our portfolio, and at the same time strengthened the company’s financial and operational foundation.”
The report is also discussed in an interview with Redeye’s analyst Fredrik Thor, which is available here: https://www.redeye.se/research/1166936/sprint-bioscience-q1-interview-positive-pipeline-development-and-increased-attention-after-trex1-deal
Download your copy or read online (in Swedish) ▪️ https://sprintbioscience.com/sv/pressmeddelande/?slug=sprint-bioscience-delarsrapport-for-januari-mars-2026

Dont forget to subscribe for future press releases ▪️ https://sprintbioscience.com/en/subscribe/

24/04/2026

Sprint Biosciences CEO Johan Emilsson presented the company and its operations at an investor event hosted by https://www.aktieinfo.net/ Aktieinfo John Stihøj in Aarhus, Denmark, on April 22. We appreciated the opportunity to share insights into our business and to meet members of the investment community, and it was very encouraging to see a strong turnout and high level of engagement from the audience in person. See the presentation and the subsequent Q&A session here 🎞️ https://sprintbioscience.com/en/movie/sprint-bioscience-presenterar-pa-aktieinfo-net-investerartraff/

22/04/2026

Today at AACR 2026 by American Association for Cancer Research (AACR) we are presenting data from our DCPS program, supporting DCPS inhibition as a promising therapeutic strategy for patients with acute myeloid leukemia (AML). The findings go beyond efficacy, providing deeper biological insight into DCPS and highlighting its potential role in improving patient stratification. Sprint Bioscience is represented by CSO Martin Andersson and Associate Principal Scientist Madhurendra Singh. Come by and discuss the data with us!
📍 Biomarkers Predictive of Therapeutic Benefit 6
🗓️ Wednesday, April 22 | Poster Section 41, Board 18

21/04/2026

At a time when the global cancer burden continues to rise, scientific progress cannot afford silos, slowdowns, or hesitation. Breakthroughs happen when knowledge is shared, challenged, and accelerated. That is why Sprint Bioscience is proud to participate in the American Association for Cancer Research (AACR) Annual Meeting 2026, the world’s largest and most influential cancer research convening.

Ahead of the main meeting, our CSO and co‑founder Martin Andersson participated in the AACR Oncology Industry Partnering Event (April 16–17), engaging with leaders across biotech and pharma. These discussions are where science meets strategy and where discoveries begin their journey toward patients.

The Annual Meeting (April 17–22) is currently underway, where Madhurendra Singh will present new preclinical data from our DCPS program. The poster highlights findings supporting DCPS inhibition as a potential therapeutic strategy for patients with acute myeloid leukemia (AML). Beyond efficacy, the data deepens the biological understanding of DCPS and underscore its potential to improve patient stratification.
🔔Wednesday, April 22 Biomarkers Predictive of Therapeutic Benefit 6 📍Location: Poster Section 41 Poster Board Number: 18

Events like AACR matter because no single lab, company, or discipline can solve cancer alone. In times of scientific complexity, geopolitical uncertainty, and mounting healthcare pressure, platforms for exchange and collaboration are not optional, they are essential.
Cancer does not wait. Neither can drug discovery.

15/04/2026

Sprint Bioscience’s Annual Report for 2025 is now available. Download your copy or read it online (in Swedish):

▪️https://sprintbioscience.com/sv/pressmeddelande/?slug=sprint-bioscience-arsredovisning
▪️Subscribe to receive future press releases and stay updated:

https://sprintbioscience.com/sv/investerare/

31/03/2026

Just in case you missed our post last week we can now proudly share it all over again because the feature in Life Science Sweden is now available in English!

▪️ Read the full article here (in English!): https://www.lifesciencesweden.se/article/view/1218102/sprint_bioscience_builds_the_molecules_that_will_become_new_medicines

The feature showcases our continued commitment to advancing innovative drug discovery and contributing to the development of future therapies. And once again, yes even this week, we’re grateful for the visibility and inspired to keep pushing the boundaries of what’s possible. 📸 Screenshot used with permission ©Life Science Sweden

27/03/2026

Sprint Bioscience are pleased to announce that groundbreaking findings from our DCPS program have once again been published, this time in the scientific journal Discover Oncology from Springer Nature. https://link.springer.com/article/10.1007/s12672-026-04880-x

“The new findings provide strong support for DCPS inhibition and clearly show how FHIT and IDH2 can be used to identify the patients who stand to benefit the most from DCPS-targeted treatment,” said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.

The article is a collaboration between Sprint Bioscience AB (publ), NeoTargets AB, and research groups led by Dr. Julian Walfridsson and Magnus Tobiasson at Karolinska Institutet. It has been partially funded by the Swedish Foundation for Strategic Research Stiftelsen för strategisk forskning, SSF through an industrial PhD fellowship.

Read the full press release here▪️https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-publishes-new-research-findings-that-strengthen-the-potential-of-dcps-inhibitors-in-aml

24/03/2026

We’re excited to share that our company is featured in Science Sweden!
Being highlighted by one of the leading media in the Nordic life science community is a proud moment for our team. The article showcases our continued commitment to advancing innovative drug discovery and contributing to the development of future therapies. A few key takeaways from the feature:

🟣 Recognition of our scientific approach and dedication to early‑stage drug development.

🟣 Spotlight on how our technology and methods can contribute to new treatment opportunities for cancer.

🟣 Acknowledgment of our team’s hard work and forward‑looking mindset.

▪️ Read the full article here (for now only available in Swedish): https://www.lifesciencesweden.se/article/view/1218102/sprint_bioscience_bygger_molekylerna_som_ska_bli_nya_lakemedel

We’re grateful for the visibility and inspired to keep pushing the boundaries of what’s possible.

Adress

Hälsovägen 7
Huddinge
14152

Telefon

+4684114455

Webbplats

http://www.sprintbioscience.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när Sprint Bioscience postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Genvägar

Vill du placera din affär längst upp i Ingenjörsföretag-listan i Huddinge?

Dela

Typ

Bioteknikföretag